ArticleJCI insight2017
Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes.
Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01299168 (Multi-centric Observational Study to Analyse the Diagnostic Molecular Features in the Clinical Setting of Kidney Allograft Biopsies), which is not on this map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-centric Observational Study to Analyse the Diagnostic Molecular Features in the Clinical Setting of Kidney Allograft Biopsies
Who cites it
77 citing papers in PubMed.
- Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Trial
- Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.Nature medicine · 2025Trial
- A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.Journal of the American Society of Nephrology : JASN · 2021Trial
- A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.Journal of the American Society of Nephrology : JASN · 2018Trial
- Biopsy-based Transcriptomics in Banff 2022 Antibody Mediated Rejection Categories.Kidney international reports · 2026Article
- Impact of older donor age in kidney transplants in a biopsy-based observational study.JCI insight · 2026Observational
- Identification of ubiquitination-related signature genes for predicting kidney transplant rejection.Scientific reports · 2026Article
- BHLHE40 Orchestrates Effector Tissue-Resident Memory CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A Subset of Pro-inflammatory CXCL10+ LILRB2+ Macrophages Derives From Recipient Monocytes and Drives Renal Allograft Rejection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Injured epithelial cell states impact kidney allograft survival after T-cell-mediated rejection.Nature communications · 2026Article
- A gene-expression module identifies circulating immune cells with enhanced recruitment to sites of inflammation.iScience · 2026Article
- The Effects of Clazakizumab on Peripheral Blood and Kidney Transcriptomes in Patients With Late Antibody-Mediated Rejection.Kidney international reports · 2025Article
- Intercenter Variability in the Application of Biopsy-based Transcriptomics in Kidney Transplantation.Transplantation direct · 2025Article
- Defining Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection.Kidney international reports · 2025Article
- Biopsy-Based Transcriptomics Support Rejection Monitoring Through Repeated Kidney Allograft Biopsies.Kidney international reports · 2025Article
- An In-depth overview of artificial intelligence (AI) tool utilization across diverse phases of organ transplantation.Journal of translational medicine · 2025Review
- Identification and Cross-Platform Validation of Sparse Molecular Classifiers for Antibody-Mediated and T-Cell-Mediated Rejection After Kidney Transplantation.Kidney international reports · 2025Article
- A cross-sectional study of the role of epithelial cell injury in kidney transplant outcomes.JCI insight · 2025Observational
- Development and Validation in Porcine and Human Models of a Bioimpedance Spectroscopy System for the Objective Assessment of Kidney Graft Viability.Sensors (Basel, Switzerland) · 2025Article
- Relating the molecular phenotype of ulcerative colitis to the clinical course.Scientific reports · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional histologic diagnosis of rejection in kidney transplants has limited repeatability due to its inherent requirement for subjective assessment of lesions, in a rule-based system that does not acknowledge diagnostic uncertainty. Molecular phenotyping affords opportunities for increased precision and improved disease classification to address the limitations of conventional histologic diagnostic systems and quantify levels of uncertainty. Microarray data from 1,208 kidney transplant biopsies were collected prospectively from 13 centers. Cross-validated classifier scores predicting the presence of antibody-mediated rejection (ABMR), T cell-mediated rejection (TCMR), and 5 related histologic lesions were generated using supervised machine learning methods. These scores were used as input for archetypal analysis, an unsupervised method similar to cluster analysis, to examine the distribution of molecular phenotypes related to rejection. Six archetypes were generated: no rejection, TCMR, 3 associated with ABMR (early-stage, fully developed, and late-stage), and mixed rejection (TCMR plus early-stage ABMR). Each biopsy was assigned 6 scores, one for each archetype, representing a probabilistic assessment of that biopsy based on its rejection-related molecular properties. Viewed as clusters, the archetypes were similar to existing histologic Banff categories, but there was 32% disagreement, much of it probably reflecting the "noise" in the current histologic assessment system. Graft survival was lowest for fully developed and late-stage ABMR, and it was better predicted by molecular archetype scores than histologic diagnoses. The results provide a system for precision molecular assessment of biopsies and a new standard for recalibrating conventional diagnostic systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.